ストックスクリーナーアプリを入手
18.57
9.26%
1.575
アフターアワーズ：
18.93
0.355
+1.91%
前日終値:
$17.00
開ける：
$17.625
24時間の取引高:
3.93M
Relative Volume:
1.66
時価総額：
$1.87B
収益：
$352.57M
当期純損益:
$-143.01M
株価収益率:
-10.26
EPS:
-1.81
ネットキャッシュフロー:
$-153.40M
1週間 パフォーマンス:
+17.34%
1か月 パフォーマンス:
+16.17%
6か月 パフォーマンス:
-30.46%
1年 パフォーマンス:
-22.83%
1日の値動き範囲:
$17.33
$18.96
1週間の範囲:
$15.68
$18.96
52週間の値動き範囲:
$13.53
$35.25
Beam Therapeutics Inc Stock (BEAM) Company Profile
名前
Beam Therapeutics Inc
セクター
電話
857-327-8775
住所
26 LANDSDOWNE STREET, CAMBRIDGE, MA
BEAM を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
BEAM
Beam Therapeutics Inc
|
18.57 | 1.64B | 352.57M | -143.01M | -153.40M | -1.81 |
|
ONC
Beone Medicines Ltd Adr
|
255.86 | 26.69B | 3.81B | -644.79M | -669.77M | -6.24 |
|
VRTX
Vertex Pharmaceuticals Inc
|
450.50 | 114.81B | 11.10B | -988.90M | -1.26B | -3.92 |
|
AKTX
Akari Therapeutics Plc Adr
|
1.232 | 41.83M | 0 | 0 | 0 | 0.00 |
|
VRNA
Verona Pharma Plc Adr
|
84.34 | 6.60B | 0 | -153.72M | -103.81M | -2.00 |
|
REGN
Regeneron Pharmaceuticals Inc
|
493.22 | 65.36B | 14.09B | 4.50B | 2.96B | 39.28 |
Beam Therapeutics Inc Stock (BEAM) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-03-28 | アップグレード | BofA Securities | Neutral → Buy |
| 2025-03-10 | アップグレード | Scotiabank | Sector Perform → Sector Outperform |
| 2025-01-29 | アップグレード | Cantor Fitzgerald | Neutral → Overweight |
| 2024-11-06 | アップグレード | Leerink Partners | Market Perform → Outperform |
| 2024-10-16 | 開始されました | Scotiabank | Sector Outperform |
| 2024-07-23 | 開始されました | H.C. Wainwright | Buy |
| 2024-01-29 | アップグレード | JP Morgan | Neutral → Overweight |
| 2023-12-15 | ダウングレード | BofA Securities | Buy → Neutral |
| 2023-12-08 | ダウングレード | Jefferies | Buy → Hold |
| 2023-10-20 | ダウングレード | Cantor Fitzgerald | Overweight → Neutral |
| 2023-10-20 | ダウングレード | Leerink Partners | Outperform → Market Perform |
| 2023-03-21 | 開始されました | Bernstein | Mkt Perform |
| 2023-02-01 | 開始されました | Cantor Fitzgerald | Overweight |
| 2022-12-20 | アップグレード | BMO Capital Markets | Market Perform → Outperform |
| 2022-12-13 | 開始されました | Citigroup | Buy |
| 2022-06-17 | 開始されました | BMO Capital Markets | Market Perform |
| 2022-04-28 | 開始されました | Credit Suisse | Neutral |
| 2022-01-05 | 開始されました | Guggenheim | Buy |
| 2021-10-19 | 開始されました | SVB Leerink | Outperform |
| 2021-09-24 | 再開されました | Stifel | Buy |
| 2021-09-10 | 開始されました | BofA Securities | Buy |
| 2021-05-11 | 開始されました | Redburn | Buy |
| 2021-05-04 | 開始されました | RBC Capital Mkts | Sector Perform |
| 2021-03-01 | ダウングレード | Barclays | Overweight → Equal Weight |
| 2021-02-16 | 開始されました | Wells Fargo | Overweight |
| 2021-01-29 | ダウングレード | JP Morgan | Overweight → Neutral |
| 2021-01-06 | 開始されました | Stifel | Hold |
| 2020-08-05 | 開始されました | William Blair | Outperform |
| 2020-03-02 | 開始されました | Barclays | Overweight |
| 2020-03-02 | 開始されました | JP Morgan | Overweight |
| 2020-03-02 | 開始されました | Jefferies | Buy |
| 2020-03-02 | 開始されました | Wedbush | Outperform |
すべてを表示
Beam Therapeutics Inc (BEAM) 最新ニュース
Beam Therapeutics (BEAM) Up 5.7% Since Last Earnings Report: Can It Continue? - Yahoo Finance
Beam Therapeutics Reports First Quarter 2025 Financial Results and Recent Business Highlights - mx.advfn.com
BEAM Up on FDA's Orphan Drug Status for Gene-Editing Therapy - Yahoo Finance
Can CRISPR Build on Casgevy's Success With Its In Vivo Pipeline? - The Globe and Mail
Beam gets FDA orphan drug status for sickle cell disease treatment - Seeking Alpha
Beam Therapeutics Says Potential Sickle Cell Therapy Receives FDA Orphan Drug Designation - marketscreener.com
Beam Therapeutics (BEAM) Gains FDA Orphan Drug Status for Sickle - GuruFocus
Beam Therapeutics’ BEAM-101 receives FDA orphan drug status for SCD treatment - Investing.com Nigeria
Beam Therapeutics Announces U.S. FDA Orphan Drug Designation Gra - GuruFocus
Beam Therapeutics Announces Orphan Drug Designation For BEAM-101 - Nasdaq
Beam Therapeutics Announces U.S. FDA Orphan Drug Designation Granted to BEAM-101 for the Treatment of Sickle Cell Disease | BEAM Stock News - GuruFocus
Beam Therapeutics Announces U.S. FDA Orphan Drug - GlobeNewswire
Breakthrough Sickle Cell Treatment BEAM-101 Secures FDA Orphan Drug Status After Strong Trial Results - Stock Titan
Top 5 CRISPR Companies To Invest In (June 2025) - Securities.io
Trading (BEAM) With Integrated Risk Controls - news.stocktradersdaily.com
Beam Therapeutics’ BEAM-302 gains FDA orphan drug status for AATD treatment By Investing.com - Investing.com South Africa
FDA Grants Orphan Drug Status to Beam Therapeutics Inc. (BEAM)’ AATD Gene Therapy - Insider Monkey
Beam Therapeutics’ BEAM-302 gains FDA orphan drug status for AATD treatment - Investing.com India
FDA Grants Orphan Drug Status to Beam Therapeutics' (BEAM) BEAM-302 | BEAM Stock News - GuruFocus
Beam receives Orphan Drug status for genetic disorder asset BEAM-302 - Seeking Alpha
Beam Therapeutics Announces U.S. FDA Orphan Drug Designation Granted To BEAM-302 For The Treatment Of Alpha-1 Antitrypsin Deficiency (AATD) - marketscreener.com
Beam Therapeutics Scores Dual FDA Wins as Orphan Drug Status Follows Promising AATD Trial Results - Stock Titan
Beam Therapeutics: A Cautious Hold On A Base Editing Pioneer (NASDAQ:BEAM) - Seeking Alpha
Shareholders May Find It Hard To Justify Increasing Beam Therapeutics Inc.'s (NASDAQ:BEAM) CEO Compensation For Now - simplywall.st
Beam Therapeutics (BEAM) Secures FDA Orphan Designation for New - GuruFocus
Beam Therapeutics (BEAM) Secures FDA Orphan Designation for New Treatment | BEAM Stock News - GuruFocus
BEAM Therapeutics’ SWOT analysis: base editing biotech stock shows promise amid challenges - Investing.com Nigeria
Analysts Have Conflicting Sentiments on These Healthcare Companies: Novo Nordisk (NVO), Beam Therapeutics (BEAM) and TScan Therapeutics (TCRX) - The Globe and Mail
Beam Therapeutics Inc. (NASDAQ:BEAM) Receives Average Recommendation of “Buy” from Analysts - Defense World
Deutsche Bank AG Has $1.67 Million Position in Beam Therapeutics Inc. (NASDAQ:BEAM) - Defense World
Post-Hoc: AI bio needs to heed the overhyped history of CRISPR - Endpoints News
(BEAM) Trading Report - news.stocktradersdaily.com
Beam Therapeutics To Present At RBC Capital Markets Global Conference; Webcast At 11:00 AM ET - Nasdaq
Mercer Global Advisors Inc. ADV Sells 4,568 Shares of Beam Therapeutics Inc. (NASDAQ:BEAM) - Defense World
Tower Research Capital LLC TRC Sells 5,172 Shares of Beam Therapeutics Inc. (NASDAQ:BEAM) - Defense World
Beam Therapeutics to Highlight New Data from BEAM-101 Program in - GuruFocus
Beam Therapeutics to Highlight New Data from BEAM-101 Program in Sickle Cell Disease at European Hematology Association (EHA) 2025 Congress | BEAM Stock News - GuruFocus
Beam Therapeutics to Present Updated Data on BEAM-101 in Sickle Cell Disease at EHA2025 Conference - Nasdaq
Beam Therapeutics to Highlight New Data from BEAM-101 - GlobeNewswire
New Clinical Data Reveals: BEAM-101 Treatment Progress in 17 Sickle Cell PatientsKey Findings Coming - Stock Titan
News: The Latest Clinical Trial Updates from CRISPR Medicine News - CRISPR Medicine News
Beam Therapeutics Inc. (NASDAQ:BEAM) Shares Purchased by Northern Trust Corp - Defense World
Beam Therapeutics Inc. (NASDAQ:BEAM) Shares Purchased by Stifel Financial Corp - Defense World
Beam Therapeutics to Participate in 2025 RBC Capital Markets Global Healthcare Conference - GlobeNewswire
Beam Therapeutics (BEAM) Gains FDA RMAT Designation for BEAM-302 - GuruFocus
Beam : FDA Grants RMAT Designation To BEAM-302 For Alpha-1 Antitrypsin Deficiency Treatment - Nasdaq
FDA grants RMAT status to Beam’s AATD gene therapy - Investing.com
Beam Therapeutics Announces U.S. FDA Regenerative Medicine - GlobeNewswire
Beam Therapeutics Announces U.S. FDA Regenerative Medicine Advanced Therapy (RMAT) Designation Granted to BEAM-302 for the Treatment of Alpha-1 Antitrypsin Deficiency (AATD) - Stock Titan
HC Wainwright Issues Positive Forecast for BEAM Earnings - Defense World
Beam Therapeutics Inc (BEAM) 財務データ
収益
当期純利益
現金流量
EPS
Beam Therapeutics Inc (BEAM) インサイダートレーディング
| インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
|---|---|---|---|---|---|---|---|
| Evans John M. | CEO |
Apr 01 '25 |
Sale |
18.35 |
30,663 |
562,684 |
986,249 |
| Ciaramella Giuseppe | President |
Apr 01 '25 |
Sale |
18.35 |
7,434 |
136,418 |
190,216 |
| Cavanagh Bethany J | SVP, Finance and Treasurer |
Apr 01 '25 |
Sale |
18.35 |
3,015 |
55,330 |
44,512 |
| Simon Amy | Chief Medical Officer |
Apr 02 '25 |
Sale |
17.73 |
20,997 |
372,294 |
65,742 |
| Simon Amy | Chief Medical Officer |
Apr 01 '25 |
Sale |
18.35 |
9,566 |
175,542 |
86,739 |
0.00%
2.33%
大文字化:
|
ボリューム (24 時間):